The indirect calorimetry in very low birth weight preterm infants: An easier and reliable procedure

Abstract Background Antenatal corticosteroids (ACS) treatment is critical to support survival and lung maturation in preterm infants, however, its effect on feeding and growth is unclear. Prior preterm delivery, it remains uncertain whether ACS treatment should be continued if possible (repeated course ACS), until a certain gestational age is reached. We hypothesized that the association of single-course ACS with feeding competence and postnatal growth outcomes might be different from that of repeated course ACS in very-low-birth-weight preterm infants. Methods A multicenter retrospective cohort study was conducted in very-low-birth-weight preterm infants born at 23–37 weeks’ gestation in South China from 2011 to 2014. Data on growth, nutritional and clinical outcomes were collected. Repeated course ACS was defined in this study as two or more courses ACS (more than single-course). Infants were stratified by gestational age (GA), including GA < 28 weeks, 28 weeks ≤ GA < 32 weeks and 32 weeks ≤ GA < 37 weeks. Multiple linear regression and multilevel model were applied to analyze the association of ACS with feeding and growth outcomes. Results A total of 841 infants were recruited. The results, just in very-low-birth-weight preterm infants born at 28–32 weeks’ gestation, showed both single and repeated course of ACS regimens had shorter intubated ventilation time compared to non-ACS regimen. Single-course ACS promoted the earlier application of amino acid and enteral nutrition, and higher rate of weight increase (15.71; 95%CI 5.54–25.88) than non-ACS after adjusting for potential confounding factors. No associations of repeated course ACS with feeding, mean weight and weight increase rate were observed. Conclusions Single-course ACS was positively related to feeding and growth outcomes in very-low-birth-weight preterm infants born at 28–32 weeks’ gestation. However, the similar phenomenon was not observed in the repeated course of ACS regimen.

Download Full-text

A pioneering study: oral clarithromycin treatment for feeding intolerance in very low birth weight preterm infants

The Journal of Maternal-Fetal & Neonatal Medicine ◽

10.1080/14767058.2017.1304908 ◽

2017 ◽

Vol 31 (8) ◽

pp. 988-992

Author(s):

Selim Sancak ◽

Tugba Gursoy ◽

Abdulhamit Tuten ◽

Didem Arman ◽

Guner Karatekin ◽

...

Keyword(s):

Birth Weight ◽

Low Birth Weight ◽

Preterm Infants ◽

Very Low Birth Weight ◽

Feeding Intolerance

Download Full-text

Late-Onset Sepsis in Very Low Birth Weight Preterm Infants: 7 years’ Experience at a Tertiary Hospital in China

Pediatrics & Neonatology ◽

10.1016/j.pedneo.2021.05.011 ◽

2021 ◽

Author(s):

Liya Ma ◽

Qiongling Peng ◽

Wei Wang ◽

Yi Yang ◽

You Chen ◽

...

Keyword(s):

Birth Weight ◽

Low Birth Weight ◽

Preterm Infants ◽

Very Low Birth Weight ◽

Late Onset ◽

Tertiary Hospital ◽

Late Onset Sepsis

Download Full-text

Comparison of Different Growth Curves in the Assessment of Extrauterine Growth Restriction in Very Low Birth Weight Preterm Infants

SSRN Electronic Journal ◽

10.2139/ssrn.3975614 ◽

2021 ◽

Author(s):

Aybuke Yazici ◽

Mehmet Buyuktiryaki ◽

Fatma Nur Sarı ◽

Mustafa Senol Akın ◽

Omer Ertekin ◽

...

Keyword(s):

Birth Weight ◽

Low Birth Weight ◽

Preterm Infants ◽

Very Low Birth Weight ◽

Growth Curves ◽

Growth Restriction ◽

Extrauterine Growth Restriction

Download Full-text

How does higher compare with lower amino acid intake in parenteral nutrition for very low birth weight or very preterm infants?

Cochrane Clinical Answers ◽

10.1002/cca.2181 ◽

2018 ◽

Author(s):

Nai Ming Lai

Keyword(s):

Birth Weight ◽

Amino Acid ◽

Low Birth Weight ◽

Parenteral Nutrition ◽

Preterm Infants ◽

Very Low Birth Weight ◽

Very Preterm Infants ◽

Very Preterm ◽

Acid Intake ◽

Amino Acid Intake

Download Full-text

Recombinant Human Erythropoietin Stimulates Erythropoiesis and Reduces Erythrocyte Transfusions in Very Low Birth Weight Preterm Infants

PEDIATRICS ◽

10.1542/peds.95.1.1 ◽

1995 ◽

Vol 95 (1) ◽

pp. 1-8

Author(s):

Kevin M. Shannon ◽

Julian F. Keith ◽

William C. Mentzer ◽

Richard A. Ehrenkranz ◽

Mark S. Brown ◽

...

Keyword(s):

Placebo Group ◽

Birth Weight ◽

Low Birth Weight ◽

Preterm Infants ◽

Recombinant Human Erythropoietin ◽

Very Low Birth Weight ◽

Group Versus ◽

Weekly Dose ◽

Human Erythropoietin ◽

Transfusion Requirements

Design and methods. We hypothesized that treatment with recombinant human erythropoietin (r-HuEPO) would stimulate erythropoiesis and would thereby reduce the need for erythrocyte transfusions in preterm infants. We treated 157 preterm infants born at 26.9 ± 1.6 weeks of gestation who weighed 924 ± 183 g at birth with either subcutaneous r-HuEPO (100 U/kg/d, 5 days per week) or placebo for 6 weeks in a randomized, double-blind, controlled clinical trial. All patients received oral iron and were managed according to uniform conservative transfusion guidelines. Results. Treatment with r-HuEPO was associated with fewer erythrocyte transfusions (1.1 ± 1.5 per infant in the r-HuEPO group versus 1.6 ± 1.7 per infant in the placebo group; P = .046) and with a reduction in the volume of packed erythrocytes transfused (16.5 ± 23.0 mL versus 23.9 ± 25.7 mL per infant; P = .023). Overall, 43% of the infants in the r-HuEPO group and 31% of placebo-treated infants were transfusion-free during the study (P = .18). The volume of blood removed for laboratory tests and the need for respiratory support at the start of treatment had major effects on transfusion requirements independent of r-HuEPO. Reticulocyte counts were higher during treatment in the r-HuEPO group (P = .0001), and r-HuEPO-treated infants had higher hematocrit values at the end of the study (32% versus 27.3% in the placebo group; P = .0001). We found no differences in the incidence of major complications of prematurity between the treatment groups. Conclusion. We conclude that treatment with r-HuEPO at a weekly dose of 500 U/kg stimulates erythropoiesis, moderates the course of anemia, is associated with a reduction in erythrocyte transfusions, and appears safe in very low birth weight preterm infants who are receiving iron supplements. Conservative transfusion criteria, minimization of phlebotomy losses, and treatment with r-HuEPO are complementary strategies to reduce erythrocyte transfusions in these infants.

Download Full-text